

WHAT IS CLAIMED IS:

1. A process for providing a human patient with an agent, comprising:
administering an agent to a human patient by providing the patient with human primary cells genetically engineered to include DNA encoding said agent for expression of said agent in vivo.
2. The process of Claim 1 wherein said human primary cells are human primary nucleated blood cells.
3. The process of Claim 2 wherein said cells are leukocytes.
4. The process of Claim 2 wherein said cells are lymphocytes.
5. The process of Claim 2 wherein said cells are T-lymphocytes.
6. The process of Claim 2 wherein the cells are TIL cells.
7. The process of Claim 2 wherein the cells are B-lymphocytes.
8. The process of Claim 1 wherein the cells have been genetically engineered in vitro.
9. The process of Claim 8 wherein said cells have been genetically engineered with a retroviral vector including RNA corresponding to said DNA.
10. The process of Claim 8 wherein the genetically engineered cells are administered to the patient intravenously.
11. The process of Claim 2 wherein the cells are genetically engineered to include DNA encoding a cytokine.
12. The process of Claim 11 wherein the cytokine is TNF.
13. The process of Claim 11 wherein the cytokine is an interleukin.

14. The process of Claim 1 wherein the agent is a therapeutic agent.

15. Human primary cells genetically engineered to include DNA encoding an agent.

16. The cells of Claim 15 wherein the cells are human primary nucleated blood cells.

17. The cells of Claim 16 wherein the cells are leukocytes.

18. The cells of Claim 16 wherein said cells are lymphocytes.

19. The cells of Claim 16 wherein the cells are T lymphocytes.

20. The cells of Claim 16 wherein said cells are TIL cells.

21. The cells of Claim 16 wherein said cells are B-lymphocytes.

22. The cells of Claim 15 wherein the agent is a therapeutic agent.

23. The cells of Claim 22 wherein the cells have been genetically engineered with a retroviral vector which includes RNA corresponding to said DNA.

24. A composition for administration to a human patient comprising:
the cells of Claim 15 and a pharmaceutically acceptable carrier.

25. The process of Claim 1 wherein said human primary cells are human primary tumor cells.

26. The cells of Claim 15 wherein the cells are human primary tumor cells.

insert

a1

insert
a2